Pathophysiological Mechanisms in Heart Failure and Cirrhosis

Altered Hemodynamics and Volume Status

The American Journal of Kidney Diseases reports that reduced effective arterial blood volume activates baroreceptors, upregulating the renin-angiotensin-aldosterone system (RAAS) and sympathetic activity, leading to systemic vasoconstriction and renal sodium retention to preserve circulation 1
The American Journal of Kidney Diseases also notes that angiotensin II causes preferential vasoconstriction of the efferent renal arterioles, reducing kidney blood flow but attempting to maintain glomerular filtration rate 1

The American Heart Association, as reported in Circulation, recommends loop diuretics as the cornerstone of managing fluid retention in both heart failure and cirrhosis, as they increase sodium excretion up to 20-25% of the filtered load and maintain efficacy unless renal function is severely impaired 5
The Hepatology journal suggests that fluid restriction is not necessary in treating most patients with cirrhosis and ascites, but severe hyponatremia (serum sodium ≤120-125 mmol/L) may warrant fluid restriction 4
The American Journal of Kidney Diseases recommends guideline-directed medical therapy, including SGLT2 inhibitors, to help with decongestion and diuretic efficacy in heart failure patients 1
The Clinical and Molecular Hepatology journal notes that vasopressin V2 receptor antagonists (vaptans) can directly antagonize the effects of elevated plasma AVP concentrations at the renal collecting ducts, but caution is needed when using vaptans in patients with liver cirrhosis as metabolism may be approximately 60% slower in uncompensated cirrhosis 3